

Study on lead generation for IPF (idiopathic pulmonary fibrosis) drug based on AI platform

INNOVO Therapeutics



RESPIRATORY	Lead
Product Type	Small molecule
Indication	1st indication: Idiopathic Pulmonary Fibrosis (IPF)
Target	Chitotriosidase (CHIT1)
MoA (Mechanism of Action)	Pharmacological inhibition of CHIT1 → Modulation of TGF- β -driven fibrotic responses → Anti-fibrotic effects
Competitiveness	First In Class <ul style="list-style-type: none"> • Potentially more effective and less toxic therapeutic drug compared to current treatment • CHIT1 could be novel therapeutic target to reverse established lung fibrosis
Development Stage	Lead
Route of Administration	Oral Administration